ГАУЭР Уильям Ф. (US),КРАФФТ Грант А. (US),ПРЭЙ Тодд (US)
申请号：
RU2012120904/15
公开号：
RU2012120904A
申请日:
2012.05.22
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. The use of a compound of formula I: wherein R represents phenyl substituted in the 2-position substituent selected from the substituent group consisting of hydroxyl and methoxy, or phenyl substituted at the position4 and bromine, or R represents a structural fragment: L is a covalent bond or -NHC (O) -, a linear or iRpredstavlyaet razvletvlenny C-alkyl or cyclohexyl, in the preparation of a medicament for improving cognitive function in a patient with decreased cognitive function, which is a consequence of neurotoxicity ADDL.2 proteins. Use according to claim 1, wherein the compound comprises R, selected from the group consisting of ethyl, propyl, butyl, pentyl, isoamyl, hexyl and tsiklogeksil.3. Use according to claim 1, wherein the deterioration of cognitive function in a patient is a consequence of a disease selected from the group consisting of Alzheimers disease, Downs syndrome, stroke, mild cognitive impairment, focal ischemia associated with dementia, and neuronal distrofiyu.4. Use according to claim 3, wherein the disease is selected from the group including Alzheimers disease, Downs syndrome, stroke, mild cognitive narusheniya.5. Use according to claim 1, wherein the deterioration of cognitive function in a patient associated with a disease or risk of disease mediated by the formation and / or activity ADDL.6 proteins. Use according to claim 1, wherein the deterioration of cognitive function in a patient is a consequence of a disease associated with insoluble amyloid fibrils, senile plaques and / or neurofibrillary klubkami.7. Use according to claim 6, wherein the disease is selected from the group consisting of focal ischemia associated with a mediated formation and / or activity ADDL.6 proteins. Use according to claim 1, wherein the deterioration of cognitive function in a patient is a consequence of a disease associated with insoluble amyloid fibrils, senile plaques and / or neurofibrillary klubkami.7. Use according to claim 6, wherein the disease is
